The Measures to Optimize RAAS-blockade in Patients with Hyperkalemia and Chronic Kidney Disease - MorphCKD

Henrik Birn0 个研究点目标入组 140 人开始时间: 2020年4月24日最近更新: 2024年2月19日

适应症

试验速览

暂无简介。

•1.Age 18-80 years
•2.eGFR 25-60 mL/min/1.73 m2
•3.Latest P-potassium > 4.5 mmol/L or b) P-kalium > 4.5 mmol/L at least twice within the last 24 months
•4.Urine albumin creatinine ratio > 500 mg/g or 200mg/g and diabetes
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 70
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 70

•1.Intolerance or allergic to Losartan, Spironolactone or Patiromer
•2.Previous renal transplant recipient or active on the waiting ling
•3.End stage renal disease (defined as the need for dialysis or renal transplantation)
•4.Any condition that currently or through the duration of the study would require specific immunosuppressive therapy
•5.Pregnancy
•6.Regular use of Trimethoprim and/or NSAIDs
•7.Disseminated cancer disease
•8.Addisons disease
•9.History of heart failure defined as Ejection Fraction (EF) < 40% or currently receiving treatment at a heart failure clinic or similar
•10.Porphyria
•11.Severe constipation requiring daily and chronic use of laxatives and/or previous recurrent ileus (> 1 incident in the past 10 years without curative treatment
•12.Fructose intolerance
•13.Galactose intolerance
•14.A history of severe liver insufficiency (Child–Pugh score B-C)
•15. SGLT2-inhibitor treatment initated = 30 days prior to inclusion

发起方

Henrik Birn